Form 4: Arcus Biosciences Director David Lacey Receives Significant Equity Compensation

Arcus Biosciences, Inc. Director David L. Lacey was granted 13,300 restricted stock units and 38,300 stock options on June 10, 2025, as detailed in a recent SEC Form 4 filing.

Summary

• David L. Lacey, a Director of Arcus Biosciences, Inc. (RCUS), was granted equity awards on June 10, 2025.
• He acquired 13,300 shares of common stock in the form of restricted stock units (RSUs) at a reported price of $0.
• These RSUs are set to vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, with full vesting also triggered upon a change in control of the company.
• Additionally, he acquired 38,300 stock options with an exercise price of $10.02.
• These stock options will vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, and will become fully vested and exercisable upon a change in control.
• Following these transactions, David Lacey beneficially owns 70,952 shares of common stock and 38,300 stock options.
• A Power of Attorney was executed by David Lacey on June 10, 2025, appointing several individuals, including company officers and legal counsel, to file SEC forms on his behalf.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive sign of continued alignment between management and shareholder interests. It's a standard compensation event, not indicative of major positive or negative news, but generally viewed favorably as it incentivizes long-term performance.

Positives

• The grant of 13,300 restricted stock units (RSUs) to a director aligns management's interests with long-term shareholder value.
• The grant of 38,300 stock options with an exercise price of $10.02 provides a direct incentive for the director to contribute to future stock price appreciation.
• The accelerated vesting provisions for both RSUs and options upon a change in control offer a potential benefit to the recipient and can facilitate corporate transactions.

Risks

• The document contains a standard legal reminder that intentional misstatements or omissions of facts constitute Federal Criminal Violations, as per 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Future Outlook

The vesting schedules for the granted restricted stock units and stock options extend to at least June 10, 2026, or the next annual meeting, indicating a future incentive structure for the director. The accelerated vesting upon a change in control suggests a potential future corporate event could impact the timing of full vesting.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, which is a common practice in the biotechnology and pharmaceutical industry. Such grants are a standard component of compensation packages designed to retain key talent and align executive and director interests with long-term shareholder value in a highly competitive sector.

Comparison to Industry Standards

• Equity grants to directors, including a mix of restricted stock units and stock options, are a standard compensation practice across the biotechnology and broader public company landscape.
• The specific amounts and vesting schedules are typically benchmarked against peer companies of similar size and stage of development within the biopharmaceutical sector, though this filing does not provide specific comparative data.
• The inclusion of change-of-control vesting provisions is also a common feature in executive and director compensation plans to provide security in the event of an acquisition.

Corporate Governance

Related Party Transactions

• The equity grant itself represents a transaction between the company and a related party (a director), which is a standard form of compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, as the value of the awards is directly tied to the company's stock performance, incentivizing long-term value creation.
• Management: The grant is a component of the compensation structure for a key director, designed to retain talent and incentivize continued commitment and performance.

Next Steps

• Vesting of restricted stock units and stock options on the earlier of June 10, 2026, or the next annual meeting of stockholders.
• Potential accelerated vesting of equity awards in the event of a change in control of Arcus Biosciences, Inc.

Key Dates

Recommendation

Keywords

Arcus Biosciences, RCUS, SEC Form 4, Insider Transaction, David Lacey, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, Corporate Governance